This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
bioMérieux, a world leader in in vitro diagnostics, has announced the lease signing of a new, 32,000-sq-ft, state-of-the-art molecular innovation center at the Navy Yard in Philadelphia, tripling the company’s footprint. In addition to supporting legacy molecular solutions, the new site will house bioMérieux’s rapidly growing xPRO™ Program, as well as the company’s Predictive Diagnostics Innovation Center, reflecting the company’s continued commitment to custom, cutting-edge, molecular diagnostic testing solutions in a fraction of the time.
Development of an average molecular assay is a laborious process that takes two to three years to release into the market. bioMérieux’s xPRO™ team comes alongside industry heavyweights to solve their problems in as little as 90 days.
“Expansion of bioMérieux’s presence in Philadelphia is essential to maintain the pace of innovation and meet the dynamic needs of our global customers,” says Ben Pascal, head of xPRO™ at bioMérieux.
With a goal of releasing multiple xPRO™ innovations into the market this year, the Predictive Diagnostics Innovation Center in Philadelphia will house the 50 person xPRO™ team, as the program continues to gain popularity among quality assurance executives in the dietary supplements, cannabis, food, and beverage segments.
The xPRO™ Program will continue its advancement under Ben Pascal. With more than two decades of experience, Pascal co-founded the highly respected biotechnology company Invisible Sentinel, which was acquired by bioMérieux in 2019.
bioMérieux's xPRO™ Program is open to all dietary supplement, cannabis, food, and beverage companies of any size that are looking to improve their quality assurance and diagnostic testing services.
